Inventor · disambiguated record
Long Mao
Also filed as: MAO LONG
26 granted patents·3 pending applications·188 citations·filing 2000–2024
96Inventor score
Files withACEA BIOSCIENCES INC10ACEA THERAPEUTICS INC9NEUROGENETIC PHARMACEUTICALS I2BRISTOL MYERS SQUIBB CO1BRISTOL MYERS SQUIBB PHARMA CO1
Top patents by PatentIndex Score
29 records- 0193US9464089B2Heterocyclic compounds and uses thereofACEA BIOSCIENCES INC·Filed 2014·Granted Oct 11, 2016·12 cites·19 claims
- 0291US9920074B2Heterocyclic compounds and uses thereofACEA BIOSCIENCES INC·Filed 2016·Granted Mar 20, 2018·6 cites·21 claims
- 0391US7781442B2Compounds and uses thereof in modulating amyloid betaNEUROGENETIC PHARMACEUTICALS I·Filed 2007·Granted Aug 24, 2010·20 cites·21 claims
- 0490US10596174B2Pyrrolopyrimidine compounds as inhibitors of protein kinasesACEA BIOSCIENCES INC·Filed 2017·Granted Mar 24, 2020·4 cites·7 claims
- 0590US9763949B2EGFR modulators and uses thereofACEA BIOSCIENCES INC·Filed 2015·Granted Sep 19, 2017·8 cites·32 claims
- 0690US8685988B2EGFR modulators and uses thereofACEA BIOSCIENCES INC·Filed 2013·Granted Apr 1, 2014·11 cites·5 claims
- 0790US7799808B2α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefromNEUROGENETIC PHARMACEUTICALS I·Filed 2007·Granted Sep 21, 2010·17 cites·26 claims
- 0889US9034885B2EGFR modulators and uses thereofACEA BIOSCIENCES INC·Filed 2013·Granted May 19, 2015·11 cites·23 claims
- 0988US11007197B2EGFR modulators and uses thereofACEA THERAPEUTICS INC·Filed 2019·Granted May 18, 2021·2 cites·18 claims
- 1088US8017629B2Compounds and uses thereof in modulating amyloid βNEUROGENETIC PHARMACEUTICALS INC·Filed 2010·Granted Sep 13, 2011·16 cites·29 claims
- 1188US7244739B2Compounds and uses thereof in modulating amyloid betaTORREYPINES THERAPEUTICS INC·Filed 2004·Granted Jul 17, 2007·35 cites·48 claims
- 1286US8119680B2α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefromCHENG SOAN·Filed 2010·Granted Feb 21, 2012·13 cites·25 claims
- 1384US10449196B2EGFR modulators and uses thereofACEA BIOSCIENCES INC·Filed 2017·Granted Oct 22, 2019·3 cites·19 claims
- 1484US9586965B2Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinasesACEA BIOSCIENCES INC·Filed 2013·Granted Mar 7, 2017·8 cites·30 claims
- 1580US10562918B2Heterocyclic compounds and uses thereofACEA BIOSCIENCES INC·Filed 2018·Granted Feb 18, 2020·3 cites·14 claims
- 1676US10533011B2Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making sameACEA THERAPEUTICS INC·Filed 2016·Granted Jan 14, 2020·4 cites·25 claims
- 1775US11987554B2Protease inhibitors as antiviralsACEA THERAPEUTICS INC·Filed 2023·Granted May 21, 2024·0 cites·16 claims
- 1875US10799504B2Heterocyclic compounds and uses as anticancer agentsACEA BIOSCIENCES INC·Filed 2013·Granted Oct 13, 2020·2 cites·8 claims
- 1974US2025122153A1Protease Inhibitors as AntiviralsACEA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2073US7276526B2Substituted thiazoles and oxazoles as corticotropin releasing hormone ligandsBRISTOL MYERS SQUIBB PHARMA CO·Filed 2002·Granted Oct 2, 2007·6 cites·8 claims
- 2171US11753373B2Protease inhibitors as antiviralsACEA THERAPEUTICS INC·Filed 2022·Granted Sep 12, 2023·0 cites·18 claims
- 2267US11612602B2Heterocyclic compounds and uses as anticancer agentsACEA THERAPEUTICS INC·Filed 2020·Granted Mar 28, 2023·0 cites·20 claims
- 2365US7297708B2Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligandsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Nov 20, 2007·3 cites·8 claims
- 2464US6984643B22,5-substituted pyrimidine derivatives-CCR-3 receptor antagonistsROCHE PALO ALTO LLC·Filed 2003·Granted Jan 10, 2006·2 cites·22 claims
- 2564US6514760B1Jointless gene of tomatoUNIV CLEMSON·Filed 2000·Granted Feb 4, 2003·2 cites·17 claims
- 2656US2025136576A1Heterocyclic Compounds and Uses ThereofACEA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2747US12358895B2Process for manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and formulations thereofACEA THERAPEUTICS INC·Filed 2018·Granted Jul 15, 2025·0 cites·18 claims
- 2841US11498922B2Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamideACEA THERAPEUTICS INC·Filed 2017·Granted Nov 15, 2022·0 cites·16 claims
- 2936US2011207751A1Heterocyclic compounds and uses as anticancer agentsMAO LONG·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Long Mao files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →